1421372-03-3

Upstream product

• 1421372-04-4 (2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl)carbamic acid tert-butyl ester 
• 1421372-05-5 2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrobenzoic acid 
• 109-01-3 1-methyl-piperazine 
• 115919-39-6 2-methoxy-4,5-dinitrobenzoic acid 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 

Downstream Products

• 1421372-01-1 N'-[4-(1H-indol-3-yl)-5-methylpyrimidin-2-yl]-4-methoxy-6-(4-methylpiperazin-1-yl)benzene-1,3-diamine 
• 1421372-35-1 6-methoxy-4-(4-methylpiperazin-1-yl)-N₁-(4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 1421372-40-8 1-[5-amino-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]guanidine 
• 1421373-40-1 C₂₈H₃₁N₇O₂ 
• 1421373-53-6 N-(4-methoxy-2-(4-methylpiperazin-1-yl)-5-(4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide 
• 1421372-02-2 4-(1H-indol-3-yl)-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]-5-methylpyrimidin-2-amine 
• 1421372-41-9 1-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]guanidine 

Relevant academic research and scientific papers

Multi-fused ring EGFR inhibitor and preparation method and application thereof

The present invention relates to a multi-fused ring EGFR inhibitor and preparation method and application thereof. In particular, the present invention relates to an EGFR inhibitor having a structure of formula (I) and a method of preparation thereof, a p

Application of benzimidazole derivative used as inhibitor of cyclin dependent kinase 4/6

The invention relates to an application of a benzimidazole derivative used as an inhibitor of cyclin dependent kinase 4/6. The benzimidazole derivative provided by the invention has a structure as shown in a formula (I) which is described in the specification. In the formula (I), substituents are described in the description.

COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.